Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

Published:2024-07 Issue: Volume: Page:
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Zhou Dian,Sun Qian,Xia Jieyun,Gu Weiying,Qian Jun,Zhuang Wanchuan,Yan Zhiling,Cheng Hai,Chen Wei,Zhu Feng,Qi Kunming,Li Depeng,Sang Wei,Zhu Lili,Ma Sha,Li Hujun,Zhang Huanxin,Qiu Tingting,Yan Dongmei,Zhang Yanlei,Peng Shuixiu,Chang Alex H,Xu Kailin,Li Zhenyu

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference32 articles.

1. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma;Carpenter;Clin Cancer Res,2013

2. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma;Ali;Blood,2016

3. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma;Yang;Cancer Lett,2023

4. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma;Brudno;J Clin Oncol,2018

5. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma;Raje;N Engl J Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?;The Lancet Haematology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP